Roy S. Herbst, MD, PhD, a professor of Medicine at Yale Cancer Center and chief of Medical Oncology at Smilow Cancer Hospital at Yale-New Haven in Connecticut, comments on the emergence of immunotherapies for multiple types of cancer including MPDL3280A for non-small cell lung cancer (NSCLC).
Herbst presented data on MPDL3280A, which targets PD-L1. This agent produced a 21% response rate for patients with multiple solid tumors, including NSCLC, and had an acceptable toxicity profile.
These data, along with other data from anti-PD-L1 agents, offers great promise of patients with NSCLC. Herbst says researchers and physicians now have new avenues for the treatment of this disease.
MPDL3280A produced a 21% response rate for patients with multiple solid tumors, including NSCLC
MPDL3280A had an acceptable toxicity profile, with only a few patients having immune-related events
These data, along with other data from anti-PD-L1 agents, offers great promise of patients with NSCLC
Edward S. Kim, MD, chairman, Solid Tumor Oncology and Investigational Therapeutics, Levine Cancer Institute, Carolinas HealthCare System, discusses some of the challenges researchers face when it comes to biomarkers in lung cancer.
Lawrence Fong, MD, associate professor, Department of Medicine (Hematology/Oncology), University of California, San Francisco, discusses research to examine the immunobiology and biomarkers associated with improved clinical outcomes seen during treatment with an anti-CTLA-4 antibody.
The investigational CD19-targeted chimeric antigen receptor (CAR) therapy CTL019 has received a breakthrough therapy designation from the FDA as a potential treatment for pediatric and adult patients with relapsed/refractory acute lymphoblastic leukemia (ALL).